The global drug discovery informatics market size was valued at USD 2.39 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.3% from 2021 to 2028. The drug discovery informatics market is set to gain momentum in the coming years due to advancements in high-performance computing & web services, increasing adoption of in-silico modeling tools, the growing volume of drug discovery data, and rising demand for novel medicine moieties. The launch of advanced drug discovery information technology is set to intensify the industry competition. For instance, in January 2021, Certara, Inc. launched Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform version 20. The new models help in assessing and analyzing the drug action during pregnancy and lactation.
In addition, it helps the customers with critical decisions regarding optimizing medicine safety and efficacy profile. Companies are also increasingly adopting informatics solutions to shorten the long drug discovery timeline. For instance, in December 2020, Curve Therapeutics Ltd. implemented the CDD Vault platform for managing its genetically encoded Microcycle platform. It is a ubiquitous hosted platform suitable for applications across pharmaceutical, biotechnology, and academic institutes for securing and seamless sharing of data in real-time, thereby facilitating collaborative discoveries.
Moreover, the accelerated Covid-19 drug discovery around the world is further contributing to the market growth. For instance, for providing fast-track solutions, scientists performed virtual screening using medicine from the DrugBank, for targeting the viral proteins and human ACE2 receptors. These studies were based on in silico tools for screening small molecules that have the potential usage in drug discoveries against Covid-19.
Similarly, companies are developing several web services & solutions for supporting various steps of drug development for Covid-19. For instance, in June 2020, the IBM visual molecular explorer platform explored a selected set of the generated molecules targeting the coronavirus (SARS-CoV-2). The open-source sharing of the AI-generated artefacts in the explorer helped in the initial stages of optimal medicine designing.
The discovery informatics dominated the market in 2020 with a revenue share of 59.19% due to a major focus on the development of precision medicines. Precision medicine involves specific medical care based on the patients’ genetic and molecular profiling. Companies, such as PerkinElmer, Inc., provide discovery informatics solutions for leveraging analytics for rapid drug discovery.
In addition, the governments in several developing countries are promoting the application of bioinformatics for rapid medicine discovery. For instance, in July 2020, the government of India launched Drug Discovery Hackathon (DDH). It is a training program for promoting the discovery of an effective molecule against the Covid-19 virus with the application of drug discovery informatics tools that have potential applications in identification, validation, and designing & molecule synthesis of the lead molecule.
The drug development workflow segment is expected to register the fastest CAGR of 11.69% from 2021 to 2028 owing to an increasing number of medicine candidates in the pipeline for pharmaceutical companies. These tools are used to perform specific tasks in clinical trial designing for promising the greatest improvement of overall trial performance.
The outsourced mode segment dominated the market in 2020 with a revenue share of 51.21%. The segment will expand further at a steady CAGR during the forecast period on account of an increasing number of partnerships between pharmaceutical companies and contract development and manufacturing organizations (CDMOs). Contract Research Organizations (CROs) are involved in the creation of reports on new drug entities that are subsequently used by the sponsor or drug manufacturer for submitting to the U.S. FDA.
There are benefits when pharmaceutical & biotechnology companies partner with a CRO that has the same informatics solution. The shared informatics platform between the CRO and companies helps in monitoring the progress of studies in the same way as their internal studies. This helps the company in cost-saving and productivity gain, which is expected to offer the market entities immense profitable opportunities.
The in-house mode segment is expected to witness the fastest CAGR of 11.73% from 2021 to 2028 due to the increasing adoption of informatics by large-scale companies for drug discovery owing to its advantages, such as providing direct access to information from a wide variety of sources, avoiding lengthy data compilation & reformatting, and helps in combining cross-disciplinary information.
The sequence analysis platforms emerged as a dominant segment with a revenue share of 35.22% in 2020. The segment will retain the dominant position registering the fastest CAGR over the forecast period. Bioinformatic solutions are widely employed for the development of primary & secondary databases of nucleic acid, protein as well as other biomolecule sequences. With the application of informatics software, mining and warehousing of genome sequencing is done for identifying genes and targeted proteins, which will help in the development of potential drugs.
In addition, basic drug discovery research requires the employment of different databases along with sequence analysis tools, such as CLUSTALW, BLAST, and FASTA. Also, the launch of new and advanced software is contributing to the segment growth. For instance, in July 2019, Certara launched a new version of D360, a scientific informatics platform (version 19.6) for drug discovery & development. The platform enables alignment, representation, and analysis of small sections of proteins and peptide sequences.
The informatics platform enables users to arrange peptide sequences based on color code by property. Molecular modeling is increasingly gaining popularity owing to its wide application in the drug discovery process. These tools are applied for the modeling and simulation of biological systems and small molecules for understanding & predicting their behavior at a molecular level. In addition, they accelerate the cost-efficiency of hit discovery and hit-to-lead optimization.
North America accounted for the largest market share of 39.30% in 2020; growth in the region can be attributed to several factors, such as high incidence of infectious diseases, rapid adoption of new & advanced tools for R&D, and the presence of prominent players. Moreover, companies in the region are focusing on joint ventures and research collaborations, which will boost the market growth in the coming years.
For instance, in December 2020, Atomwise Inc. unveiled a growing portfolio of joint venture companies including vAirus, OrganAi, and A2i Therapeutics, with programs spanning infectious disease, immunology, oncology, clotting disorders, and neuroscience. Asia Pacific is projected to be the fastest-growing regional market from 2021 to 2028.
Key players are increasingly engaging in collaborations with other companies, research institutes, and clinical research organizations for promoting rapid drug development. For instance, in March 2020, Charles River Laboratories International, Inc. entered in partnership with Deciphex. Deciphex’s Patholytix Preclinical platform will help in maximizing pathologist productivity and delivering data faster to clients. This helped expand the company’s portfolio in the market. Some key participants in the global drug discovery informatics market include:
Certara
Boehringer Ingelheim International GmbH
Infosys Ltd.
Charles River Laboratories
Collaborative Drug Discovery, Inc.
Eurofins DiscoverX Products
Jubilant Biosys
Selvita
Novo Informatics Pvt. Ltd.
ChemAxon Ltd.
Albany Molecular Research Inc.
Oracle
Accenture
Agilent Technologies, Inc.
Illumina, Inc.
Report Attribute |
Details |
Market size value in 2021 |
USD 2.67 billion |
Revenue forecast in 2028 |
USD 5.63 billion |
Growth rate |
CAGR of 11.3% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Workflow, mode, services, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Japan; China; India; Brazil; South Africa |
Key companies profiled |
Certara; Boehringer Ingelheim International GmbH; Infosys Ltd.; Charles River Laboratories; Collaborative Drug Discovery, Inc.; Eurofins DiscoverX Products; Jubilant Biosys; Selvita; Novo Informatics Pvt. Ltd.; ChemAxon Ltd.; Albany Molecular Research Inc.; Oracle; Accenture; Agilent Technologies, Inc.; Illumina, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global drug discovery informatics market report on the basis of workflow, mode, services, and region:
Workflow Outlook (Revenue, USD Million, 2017 - 2028)
Discovery Informatics
Identification, Validation, & Assay Development Informatics
Lead Generation
Development Informatics
Lead Optimization
FHD Preparation
Phase IA
Phase IB/2
Mode Outlook (Revenue, USD Million, 2017 - 2028)
Outsourced
In-house
Services Outlook (Revenue, USD Million, 2017 - 2028)
Sequence Analysis Platforms
Molecular Modeling
Docking
Clinical Trial Data Management
Other Services
Regional Outlook (Revenue, USD Million, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Latin America
Brazil
Middle East & Africa
South Africa
b. The global drug discovery informatics market size was estimated at USD 2.39 billion in 2020 and is expected to reach USD 2.67 billion in 2021.
b. The global drug discovery informatics market is expected to grow at a compound annual growth rate of 11.28% from 2021 to 2028 to reach USD 5.63 billion by 2028.
b. North America dominated the drug discovery informatics market with a share of 39.30% in 2020. This is attributable to higher incidence rates of different infectious diseases & oncology diseases and simultaneous developments of next-generation sequencing & chemical laboratories in the region.
b. Some key players operating in the drug discovery informatics market include Albany Molecular Research Inc.; Certara; Boehringer Ingelheim GmBh; Charles River Laboratories; Infosys; GVK Biosciences; Collaborative Drug Discovery Inc.; DiscoverX; ChemAxon; Jubilant Biosys; Novo Informatics; and Selvita.
b. Key factors that are driving the drug discovery informatics market growth include Increasing adoption of in-silico modeling tools, advancements in high-performance computing and web services, the growing volume of drug discovery data, and growth in demand for novel drug moieties.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.